Lung Cancer
3,123
442
580
1,546
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
409 trials with published results (13%)
Research Maturity
1546 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
285 terminated out of 3123 trials
84.4%
-2.2% vs benchmark
7%
219 trials in Phase 3/4
26%
409 of 1546 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1546 completed trials
Clinical Trials (3123)
Evaluation for NCI Surgery Branch Clinical Research Protocols
Distance-Based Exercise to Preserve Function and Prevent Disability
Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Prospective Multiomic Analysis in Small-Cell Lung Cancer
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Integrating Artificial Intelligence Into Lung Cancer Screening.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
AI-Assisted 3D Reconstruction for Lung Resection Planning
Empathic Communication Skills (ECS) Training
Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery
Augmented Endobronchial Ultrasound (EBUS-TBNA) With Artificial Intelligence
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
Lung EpiCheck Biomarkers Development Study
Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer
The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With Lung Cancer
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
Collection of Blood From Patients With Cancer